FTC Acquisition Challenges In Health Care

Law360, New York (October 2, 2009, 11:22 AM EDT) -- The Federal Trade Commission has challenged some proposed and completed acquisitions of interest this summer, three of which have resulted in the abandonment of the proposed mergers.

Lundbeck Inc. (Pharmaceutical Drugs)

The FTC defeated a motion for summary judgment in a case in which the defendant Lundbeck Inc. (“Lundbeck”) had acquired the rights to two drugs used to treat patent ductus arteriosus (“PDA”)[1], Indocin and NeoProfen, which were alleged to be the only drug therapies available for such treatment in the United States.[2]

On July 21,...
To view the full article, register now.